Skip to main content
. Author manuscript; available in PMC: 2015 Jul 1.
Published in final edited form as: Ann Intern Med. 2013 Jun 18;158(12):853–860. doi: 10.7326/0003-4819-158-12-201306180-00002

Table 5.

Base-Case Average Lifetime Costs and QALE for Men Aged 65 and 75 Years

Strategy Cost, $ Incremental Cost, $ QALE, y Incremental QALE, y Men Treated, % Died of Prostate Cancer, %
Men aged 65 y
    WW 24 520 - 9.02 - 34 6.0
    BT 35 374 10 854 8.14 −0.88 100 8.9
    RP 38 180 13 660 7.95 −1.07 100 8.9
    AS 39 894 15 374 8.85 −0.17 78 4.8
    IMRT 48 699 24 179 8.10 −0.92 100 8.9
Men aged 75 y*
    WW 18 302 - 6.14 - 23 2.6
    BT 28 810 10 508 5.56 −0.58 100 3.9
    AS 30 048 11 746 5.98 −0.16 61 2.1
    IMRT 42 286 23 984 5.52 −0.62 100 3.9

AS = active surveillance; BT = brachytherapy; IMRT = intensity-modulated radiation therapy; QALE = quality-adjusted life expectancy; RP = radical prostectomy; WW = watchful waiting.

*

RP not modeled in men aged 75 y.